Iveta Kolarova1,2, Ladislav Dusek3, Ales Ryska4, Karek Odrazka5,6,7,8,9, Martin Dolezel7,10, Jaroslav Vanasek2,5,6, Bohuslav Melichar1,10,11, Jiri Petera1,11, Tomas Buchler12, Milan Vosmik1,11, Katarina Petrakova13, Petra Terarova7,14, Zdena Vilasova5, Jiri Jarkovsky15. 1. Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. 2. Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic. 3. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 4. The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. 5. Oncology Centre, Multiscan, Pardubice, Czech Republic. 6. Department of Clinical and Radiation Oncology, Pardubice Hospital, Pardubice, Czech Republic. 7. Department of Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic. 8. Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. 9. Institute for Postgraduate Medical Education, Prague, Czech Republic. 10. Department of Oncology, Palacky University Medical School & Teaching Hospital, Olomouc, Czech Republic. 11. Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. 12. Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. 13. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. 14. Department of Oncology, General University Hospital in Prague, Prague, Czech Republic. 15. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic jarkovsky@iba.muni.cz.
Abstract
BACKGROUND/AIM: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. PATIENTS AND METHODS: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. RESULTS: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. CONCLUSION: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time. Copyright
BACKGROUND/AIM: The study aimed to evaluate differences in the overall survival of HER2+ breast cancerpatients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. PATIENTS AND METHODS: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. RESULTS: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. CONCLUSION: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time. Copyright
Authors: Edoardo Colzani; Annelie Liljegren; Anna L V Johansson; Jan Adolfsson; Henrik Hellborg; Per F L Hall; Kamila Czene Journal: J Clin Oncol Date: 2011-09-12 Impact factor: 44.544
Authors: Marco Colleoni; Zhuoxin Sun; Karen N Price; Per Karlsson; John F Forbes; Beat Thürlimann; Lorenzo Gianni; Monica Castiglione; Richard D Gelber; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2016-01-19 Impact factor: 44.544
Authors: Sharon H Giordano; Sarah Temin; Jeffrey J Kirshner; Sarat Chandarlapaty; Jennie R Crews; Nancy E Davidson; Francisco J Esteva; Ana M Gonzalez-Angulo; Ian Krop; Jennifer Levinson; Nancy U Lin; Shanu Modi; Debra A Patt; Edith A Perez; Jane Perlmutter; Naren Ramakrishna; Eric P Winer Journal: J Clin Oncol Date: 2014-05-05 Impact factor: 44.544
Authors: I Kolarova; J Vanasek; M Dolezel; J Stuk; A Hlavka; L Dusek; B Melichar; T Büchler; A Ryska; J Prausova; K Petrakova; P Tesarova; J Petera; M Vosmik; K Horackova; J Jarkovsky Journal: Neoplasma Date: 2020-07-01 Impact factor: 2.575
Authors: F Cardoso; A Costa; E Senkus; M Aapro; F André; C H Barrios; J Bergh; G Bhattacharyya; L Biganzoli; M J Cardoso; L Carey; D Corneliussen-James; G Curigliano; V Dieras; N El Saghir; A Eniu; L Fallowfield; D Fenech; P Francis; K Gelmon; A Gennari; N Harbeck; C Hudis; B Kaufman; I Krop; M Mayer; H Meijer; S Mertz; S Ohno; O Pagani; E Papadopoulos; F Peccatori; F Penault-Llorca; M J Piccart; J Y Pierga; H Rugo; L Shockney; G Sledge; S Swain; C Thomssen; A Tutt; D Vorobiof; B Xu; L Norton; E Winer Journal: Ann Oncol Date: 2017-01-01 Impact factor: 32.976